Kenan Aksu

Kenan Aksu

Auto-generated profile, based on publicly available information

Kenan Aksu

Department of Internal Medicine, Division of Rheumatology Ege University Faculty of Medicine İzmir Turkiye

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2013 in Rheumatology
Verified
Journal Article
Open access
PDF file
GKGokhan Keser
Gokhan Keser
HDHaner Direskeneli
Haner Direskeneli
KAKenan Aksu
Kenan Aksu
Assessment of the pattern and extent of arterial involvement and measurement of current disease activity are essential for the management of Takayasu arteritis (TA). Since there is no completed, placebo-controlled, randomized clinical trial, the level of evidence for management of TA is low, generally reflecting the results of open studies, case series and expert opinion. The most commonly used agents include corticosteroids and conventional immunosuppressive agents such as MTX, AZA, MMF and LEF. In patients who remain resistant and/or intolerant to these agents, biologic drugs including TNF inhibitors, rituximab and tocilizumab seem to be promising. Antiplatelet treatment may also lower the frequency of ischaemic events in TA. In the presence of short-segment, critical arterial stenosis, balloon angioplasty or stent graft replacement may be useful. On the other hand, long-segment stenosis with extensive periarterial fibrosis or occlusion requires surgical bypass of the affected segment, which is clearly associated with superior results compared with endovascular intervention. As a general rule, both endovascular intervention and surgical procedures should be avoided during the active phase of the disease. Earlier diagnosis, better assessment of disease activity and future clinical trials will obviously improve the management of TA.

1 August 2013 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
GSGüher Saruhan-Direskeneli
Güher Saruhan-Direskeneli
THTravis Hughes
Travis Hughes
KAKenan Aksu
Kenan Aksu
GKGokhan Keser
Gokhan Keser
PCPatrick Coit
Patrick Coit
ASAmr Sawalha
Amr Sawalha

10 February 2013 in Nature Genetics
Verified
Journal Article
Closed access
THTravis Hughes
Travis Hughes
PCPatrick Coit
Patrick Coit
AAAdam Adler
Adam Adler
VYVuslat Yilmaz
Vuslat Yilmaz
KAKenan Aksu
Kenan Aksu
ASAmr H Sawalha
Amr H Sawalha

24 December 2013 in Rheumatology
Verified
Journal Article
Open access
PDF file
TKTimucin Kasifoglu
Timucin Kasifoglu
SBSule Yasar Bilge
Sule Yasar Bilge
ISIsmail Sari
Ismail Sari
DSDilek Solmaz
Dilek Solmaz
SSSoner Senel
Soner Senel
CKCengiz Korkmaz
Cengiz Korkmaz
Objective. The primary aim of this study was to investigate the prevalence of amyloidosis and its related factors in a large number of FMF patients. Methods. Fifteen centres from the different geographical regions of Turkey were included in the study. Detailed demographic and medical data based on a structured questionnaire and medical records were collected. The diagnosis of amyloidosis was based on histological proof of congophilic fibrillar deposits in tissue biopsy specimens. Results. There were 2246 FMF patients. The male/female ratio was 0.87 (1049/1197). The mean age of the patients was 34.5 years (s.d. 11.9). Peritonitis was the most frequent clinical finding and it was present in 94.6% of patients. Genetic testing was available in 1719 patients (76.5%). The most frequently observed genotype was homozygous M694V mutation, which was present in 413 (24%) patients. Amyloidosis was present in 193 patients (8.6%). Male sex, arthritis, delay in diagnosis, M694V genotype, patients with end-stage renal disease (ESRD) and family history of amyloidosis and ESRD were significantly more prevalent in patients with amyloidosis compared with the amyloidosis-negative subjects. Patients with homozygous M694V mutations had a 6-fold higher risk of amyloidosis compared with the other genotypes (95% CI 4.29, 8.7, P < 0.001). Conclusion. In this nationwide study we found that 8.6% of our FMF patients had amyloidosis and homozygosity for M694V was the most common mutation in these patients. The latter finding confirms the association of homozygous M694V mutation with amyloidosis in Turkish FMF patients.

11 June 2010 in Rheumatology
Verified
Journal Article
Open access
PDF file
SASibel Z. Aydin
Sibel Z. Aydin
NYNeslihan Yilmaz
Neslihan Yilmaz
SAServet Akar
Servet Akar
KAKenan Aksu
Kenan Aksu
SKSevil Kamali
Sevil Kamali
HDHaner Direskeneli
Haner Direskeneli
Objective. Disease Extent Index-Takayasu (DEI.Tak) is a new index developed for the follow-up of Takayasu’s arteritis (TA), assessing only clinical findings without the requirement of imaging. We investigated the effectiveness of DEI.Tak in assessing disease activity and progression by comparing with physician’s global assessment (PGA) and active disease criteria defined by Kerr et al. Methods. The initial DEI.Tak forms were filled in for 145 TA patients cross-sectionally to detect the baseline damage and after 29.8 (31) months (n = 105, 144 visits) only by including the new/worsening symptoms within the past 6 months. Results. At baseline, all patients had a DEI.Tak >0 [mean (s.d. ): 7.6 (4.2)]. At this evaluation, 62% of the patients had active, 16.2% had persistent and 21.8% had inactive disease according to the PGA. At follow-up, in 69% of the patients the DEI.Tak score was 0. However, 14% of them were accepted as having active and 17% persistent disease according to PGA. In contrast, 18% with a DEI.Tak ≥ 1 were inactive according to PGA. Patients with active or persistent disease with PGA had higher DEI.Tak compared with inactives [1.3 (1.9), 1 (1.3) vs 0.2 (0.6), respectively; P < 0.001]. According to Kerr’s criteria 27% were active. The total agreement between DEI.Tak and Kerr’s criteria was 94% (κ = 0.85). Compared with PGA, Kerr’s criteria had a total agreement of 74% and DEI.Tak 68%. Conclusion. During follow-up, most TA patients showed no clinical activity with DEI-Tak. Although the agreement between Kerr’s criteria and DEI.Tak seemed very good, using Kerr’s criteria instead of DEI.Tak increased the consistency with PGA, which could be explained by the influence of imaging data and acute-phase reactant levels on the physician’s decisions.

20 January 2015 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
PRPaul A. Renauer
Paul A. Renauer
GSGuher Saruhan‐Direskeneli
Guher Saruhan‐Direskeneli
PCPatrick Coit
Patrick Coit
AAAdam Adler
Adam Adler
KAKenan Aksu
Kenan Aksu
ASAmr Sawalha
Amr Sawalha
Objective: Takayasu arteritis is a rare large vessel vasculitis with incompletely understood etiology. This study was undertaken to perform the first unbiased genome‐wide association analysis of Takayasu arteritis.Methods: Two independent cohorts of patients with Takayasu arteritis from Turkey and North America were included in our study. The Turkish cohort consisted of 559 patients and 489 controls, and the North American cohort consisted of 134 patients and 1,047 controls of European ancestry. Genotyping was performed using the Omni1‐Quad and Omni2.5 genotyping arrays. Genotyping data were subjected to rigorous quality control measures and subsequently analyzed to discover genetic susceptibility loci for Takayasu arteritis.Results: We identified genetic susceptibility loci for Takayasu arteritis with a genome‐wide level of significance in IL6 (rs2069837) (odds ratio [OR] 2.07, P = 6.70 × 10−9), RPS9/LILRB3 (rs11666543) (OR 1.65, P = 2.34 × 10−8), and an intergenic locus on chromosome 21q22 (rs2836878) (OR 1.79, P = 3.62 × 10−10). The genetic susceptibility locus in RPS9/LILRB3 lies within the leukocyte receptor complex gene cluster on chromosome 19q13.4, and the disease risk variant in this locus correlates with reduced expression of multiple genes including the inhibitory leukocyte immunoglobulin‐like receptor gene LILRB3 (P = 2.29 × 10−8). In addition, we identified candidate susceptibility genes with suggestive levels of association (P < 1 × 10−5) with Takayasu arteritis, including PCSK5, LILRA3, PPM1G/NRBP1, and PTK2B.Conclusion: Our findings indicate novel genetic susceptibility loci for Takayasu arteritis and uncover potentially important aspects of the pathophysiology of this form of vasculitis.